Osteoporosis and Long-term Etretinate Therapy

Archives of Dermatology

Volumn 132, Issue 6, 1996, Pages 713-

  Whitmore, S Elizabeth ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETINATE; KERATOLYTIC AGENT;

CHEMICALLY INDUCED DISORDER; HUMAN; NOTE; OSTEOPOROSIS; TIME; CALCIUM METABOLISM; KERATINIZATION; LETTER; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

ETRETINATE; HUMANS; KERATOLYTIC AGENTS; OSTEOPOROSIS; TIME FACTORS;

EID: 0029920005     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1996.03890300143026     Document Type: Letter

References (5)

1. DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol. 1995;131:1263-1267.
2. Milstone LM, Bale SJ, Insogna KL. Secondary hyperparathyroidism in patients with ichthyosis is not caused by vitamin D deficiency or ingestion of retinoids. Arch Dermatol. 1993;129:648.
3. Staberg B, Oxholm A, Klemp P, Christiansen C. Abnormal vitamin D metabolism in patients with psoriasis. Acta Derm Venereol (Stockh). 1987;67:65-68.
4. Morimoto S, Yoshikawa K, Fukuo K, et al. Inverse relationship between severity of psoriasis and serum 1,25-dihydroxyvitamin D level. J Dermatol Sci. 1990;1:277-282.
5. Harris SS, Dawson-Hughes B. Caffeine and bone loss in healthy postmenopausal women. Am J Clin Nutr. 1994; 60:573-578.